已收盘 05-08 16:00:00 美东时间
-1.280
-3.48%
今日重点评级关注:Citizens:维持BioCryst制药"跑赢大市"评级,目标价从25美元升至28美元;富国银行:维持曼恩凯德生物医疗"超配"评级,目标价从8美元升至10美元
05-08 12:05
Ibotta shares are trading lower. The company reported Q1 financial results.
05-07 20:55
Needham analyst Bernie McTernan maintains Ibotta (NYSE:IBTA) with a Buy and raises the price target from $33 to $45.
05-07 19:20
Companies Reporting Before The Bell • Deluxe (NYSE:DLX) is expected to report q...
05-07 05:03
Ibotta Performance Network now spans the industry's leading third-party grocery delivery providers, further solidifying its position as North America's definitive platform for CPG promotionsIbotta, Inc. (NYSE:IBTA), the
03-25 20:17
Q4净利暴增超68%!Sezzle大涨超35%;GigaCloud业绩表现亮眼,大健云仓涨超33%>>
02-27 19:46
今日重点评级关注:HC Wainwright & Co.:维持NovoCure"买入"评级,目标价从47美元升至49美元;Citizens:维持Ironwood医药"跑赢大市"评级,目标价从8美元升至10美元
02-27 11:07
Gainers Antelope Enterprise Hldgs (NASDAQ:AEHL) shares moved upwards by 108.9%...
02-27 01:05
Wells Fargo analyst Ken Gawrelski maintains Ibotta (NYSE:IBTA) with a Equal-Weight and raises the price target from $30 to $34.
02-27 00:10
<span style="color:#999999;">编者按:聚焦公司高管观点与展望,深挖业绩背后的信息,助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据Ibotta业绩会实录,以下是财务业绩回顾摘要: ## 1. 财务业绩 **营收表现:** - 总营收8,850万美元,同比下降10% - 兑换营收7,850万美元,同比下降5% - 第三方发布商兑换营收5,640万美元,同比增长8% - 直接面向消费者兑换营收2,220万美元,同比下降26% - 广告及其他营收1,000万美元,同比下降38% **盈利能力:** - 非GAAP毛利率79%,同比下降约570个基点 - 调整后EBITDA为1,370万美元,利润率15% - 调整后净收入810万美元 - 调整后稀释每股收益0.29美元 **现金流
02-26 12:28